Literature DB >> 11222710

Differences in cytokine and chemokine responses during neurological disease induced by polytropic murine retroviruses Map to separate regions of the viral envelope gene.

K E Peterson1, S J Robertson, J L Portis, B Chesebro.   

Abstract

Infection of the central nervous system (CNS) by several viruses can lead to upregulation of proinflammatory cytokines and chemokines. In immunocompetent adults, these molecules induce prominent inflammatory infiltrates. However, with immunosuppressive retroviruses, such as human immunodeficiency virus (HIV), little CNS inflammation is observed yet proinflammatory cytokines and chemokines are still upregulated in some patients and may mediate pathogenesis. The present study examined expression of cytokines and chemokines in brain tissue of neonatal mice infected with virulent (Fr98) and avirulent (Fr54) polytropic murine retroviruses. While both viruses infect microglia and endothelia primarily in the white matter areas of the CNS, only Fr98 induces clinical CNS disease. The pathology consists of gliosis with minimal morphological changes and no inflammation, similar to HIV. In the present experiments, mice infected with Fr98 had increased cerebellar mRNA levels of proinflammatory cytokines tumor necrosis factor alpha (TNF-alpha), TNF-beta, and interleukin-1 alpha and chemokines macrophage inflammatory protein-1 alpha (MIP-1 alpha), MIP-1 beta, monocyte chemoattractant protein 1 (MCP-1), gamma-interferon-inducible protein 10 (IP-10), and RANTES compared to mice infected with Fr54 or mock-infected controls. The increased expression of these genes occurred prior to the development of clinical symptoms, suggesting that these cytokines and chemokines might be involved in induction of neuropathogenesis. Two separate regions of the Fr98 envelope gene are associated with neurovirulence. CNS disease associated with the N-terminal portion of the Fr98 env gene was preceded by upregulation of cytokines and chemokines. In contrast, disease associated with the central region of the Fr98 env gene showed no upregulation of cytokines or chemokines and thus did not require increased expression of these genes for disease induction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222710      PMCID: PMC115911          DOI: 10.1128/JVI.75.6.2848-2856.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

Review 1.  Chemokines in the CNS: plurifunctional mediators in diverse states.

Authors:  V C Asensio; I L Campbell
Journal:  Trends Neurosci       Date:  1999-11       Impact factor: 13.837

Review 2.  Chemokines and their receptors in neurobiology: perspectives in physiology and homeostasis.

Authors:  K B Bacon; J K Harrison
Journal:  J Neuroimmunol       Date:  2000-04-03       Impact factor: 3.478

3.  Increased expression of MIP-1 alpha and MIP-1 beta mRNAs in the brain correlates spatially and temporally with the spongiform neurodegeneration induced by a murine oncornavirus.

Authors:  S Askovic; C Favara; F J McAtee; J L Portis
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  A polymorphism in the mouse crg-2/IP-10 gene complicates chemokine gene expression analysis using a commercial ribonuclease protection assay.

Authors:  W Hallensleben; L Biro; C Sauder; J Hausmann; V C Asensio; I L Campbell; P Staeheli
Journal:  J Immunol Methods       Date:  2000-02-03       Impact factor: 2.303

5.  Role of HIV-1 Tat and CC chemokine MIP-1alpha in the pathogenesis of HIV associated central nervous system disorders.

Authors:  R Bonwetsch; S Croul; M W Richardson; C Lorenzana; L Del Valle; A E Sverstiuk; S Amini; S Morgello; K Khalili; J Rappaport
Journal:  J Neurovirol       Date:  1999-12       Impact factor: 2.643

Review 6.  The effects of human immunodeficiency virus in the central nervous system.

Authors:  D L Kolson; E Lavi; F González-Scarano
Journal:  Adv Virus Res       Date:  1998       Impact factor: 9.937

Review 7.  Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms.

Authors:  L G Epstein; H E Gendelman
Journal:  Ann Neurol       Date:  1993-05       Impact factor: 10.422

8.  Murine leukemia virus-associated cell surface antigens in rats neonatally infected with Gross murine leukemia virus.

Authors:  R S Basch; D Grausz; N Harris; N A Mitchison
Journal:  J Natl Cancer Inst       Date:  1979-12       Impact factor: 13.506

9.  Murine retrovirus-induced spongiform encephalopathy: productive infection of microglia and cerebellar neurons in accelerated CNS disease.

Authors:  W P Lynch; S Czub; F J McAtee; S F Hayes; J L Portis
Journal:  Neuron       Date:  1991-09       Impact factor: 17.173

10.  Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat.

Authors:  E J Duh; W J Maury; T M Folks; A S Fauci; A B Rabson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

View more
  28 in total

1.  Neurovirulence of polytropic murine retrovirus is influenced by two separate regions on opposite sides of the envelope protein receptor binding domain.

Authors:  Karin E Peterson; Susan Pourciau; Min Du; Rachel Lacasse; Melissa Pathmajeyan; David Poulsen; Mavis Agbandje-McKenna; Kathy Wehrly; Bruce Chesebro
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

2.  Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma.

Authors:  Chien-Kuo Tai; Wei Jun Wang; Thomas C Chen; Noriyuki Kasahara
Journal:  Mol Ther       Date:  2005-11       Impact factor: 11.454

3.  Human Immunodeficiency virus type 1 Nef potently induces apoptosis in primary human brain microvascular endothelial cells via the activation of caspases.

Authors:  Edward A Acheampong; Zahida Parveen; Lois W Muthoga; Mehrnush Kalayeh; Muhammad Mukhtar; Roger J Pomerantz
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Neuropeptide Y Negatively Influences Monocyte Recruitment to the Central Nervous System during Retrovirus Infection.

Authors:  Tyson A Woods; Min Du; Aaron Carmody; Karin E Peterson
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

Review 5.  Immunobiology of congenital cytomegalovirus infection of the central nervous system—the murine cytomegalovirus model.

Authors:  Irena Slavuljica; Daria Kveštak; Peter Csaba Huszthy; Kate Kosmac; William J Britt; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2014-07-21       Impact factor: 11.530

Review 6.  Innate immunity in the pathogenesis of polytropic retrovirus infection in the central nervous system.

Authors:  Karin E Peterson; Min Du
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

7.  Disparate regions of envelope protein regulate syncytium formation versus spongiform encephalopathy in neurological disease induced by murine leukemia virus TR.

Authors:  Samuel L Murphy; Marek J Honczarenko; Natalie V Dugger; Paul M Hoffman; Glen N Gaulton
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Neurodegeneration induced by PVC-211 murine leukemia virus is associated with increased levels of vascular endothelial growth factor and macrophage inflammatory protein 1 alpha and is inhibited by blocking activation of microglia.

Authors:  Xiujie Li; Charlotte Hanson; Joan L Cmarik; Sandra Ruscetti
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

9.  Endogenous retroviruses mobilized during friend murine leukemia virus infection.

Authors:  Stefano Boi; Kyle Rosenke; Ethan Hansen; Duncan Hendrick; Frank Malik; Leonard H Evans
Journal:  Virology       Date:  2016-09-19       Impact factor: 3.616

10.  Infection of cardiomyocytes and induction of left ventricle dysfunction by neurovirulent polytropic murine retrovirus.

Authors:  Mohammed Khaleduzzaman; Joseph Francis; Meryll E Corbin; Elizabeth McIlwain; Marc Boudreaux; Min Du; Tim W Morgan; Karin E Peterson
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.